☰

Sukyung Woo, Ph.D. - Publications

Affiliations: 
2007 Pharmaceutical Sciences State University of New York, Buffalo, Buffalo, NY, United States 
Tree Info Similar researchers PubMed Report error

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Sharma A, Li M, Thavathiru E, Ibrahim M, Garcia-Contreras L, Benbrook DM, Woo S. Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. The Aaps Journal. 22: 51. PMID 32086622 DOI: 10.1208/S12248-020-0421-Z  0.367
2020 Lim SY, Sharan S, Woo S. Model-Based Analysis of Cannabidiol Dose-Exposure Relationship and Bioavailability. Pharmacotherapy. PMID 32058609 DOI: 10.1002/Phar.2377  0.304
2019 Subramaniyan B, Rajaputra P, Nguyen L, Li M, Peer CJ, Kindrick J, Figg WD, Woo S, You Y. Local and Systemic Antitumor Effects of Photo-activatable Paclitaxel Prodrug on Rat Breast Tumor Models. Photochemistry and Photobiology. PMID 31883393 DOI: 10.1111/Php.13202  0.308
2019 Nguyen L, Li M, Woo S, You Y. Development of Prodrugs for PDT-Based Combination Therapy Using a Singlet-Oxygen-Sensitive Linker and Quantitative Systems Pharmacology. Journal of Clinical Medicine. 8. PMID 31847080 DOI: 10.3390/Jcm8122198  0.315
2019 Li M, Nguyen L, Subramaniyan B, Bio M, Peer CJ, Kendrick J, Figg WD, Woo S, You Y. PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 31299262 DOI: 10.1016/J.Jconrel.2019.07.010  0.35
2018 Sharma A, Benbrook DM, Woo S. Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2. Plos One. 13: e0194046. PMID 29634717 DOI: 10.1371/Journal.Pone.0194046  0.356
2017 Ibach BW, Miller JL, Woo S, Harrison D, Standifer KM, Hagemann T, Johnson PN. Characterization of Tolerance in Children during Fentanyl Continuous Infusions. Journal of Pediatric Intensive Care. 6: 83-90. PMID 31073429 DOI: 10.1055/S-0036-1584909  0.301
2017 Li M, Thapa P, Rajaputra P, Bio M, Peer CJ, Figg WD, You Y, Woo S. Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system. Journal of Pharmacokinetics and Pharmacodynamics. PMID 28913666 DOI: 10.1007/S10928-017-9543-Z  0.35
2016 Thapa P, Li M, Bio M, Rajaputra P, Sun Y, Woo S, You Y. Abstract 1361: Progress in light activatable prodrug for the combinational treatment of PDT and site-specific chemotherapy: paclitaxel prodrugs Cancer Research. 76: 1361-1361. DOI: 10.1158/1538-7445.Am2016-1361  0.316
2015 Devapatla B, Sharma A, Woo S. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer. Plos One. 10: e0139237. PMID 26414070 DOI: 10.1371/Journal.Pone.0139237  0.329
2015 Sharan S, Woo S. Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities. Frontiers in Pharmacology. 6: 33. PMID 25750626 DOI: 10.3389/Fphar.2015.00033  0.327
2015 Devapatla BK, Jaiprasart P, Woo S. Abstract 1935: Gene expression analysis reveals distinct pathways of resistance to antiangiogenic therapy in ovarian cancer Cancer Research. 75: 1935-1935. DOI: 10.1158/1538-7445.Am2015-1935  0.32
2014 Devapatla BK, Sharma A, Woo S. Abstract 2999: Interleukin-8 mediates resistance to anti-VEGF therapy in ovarian cancer Cancer Research. 74: 2999-2999. DOI: 10.1158/1538-7445.Am2014-2999  0.309
2013 Vega-Villa K, Ihnat M, Woo S. Abstract 2065: Development of a general framework for effective translation of in vitro synergistic combination into in vivo synergy using a systemic modeling approach. Cancer Research. 73: 2065-2065. DOI: 10.1158/1538-7445.Am2013-2065  0.382
2012 Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2344-51. PMID 22371451 DOI: 10.1158/1078-0432.Ccr-11-2425  0.306
2011 Pluta RM, Oldfield EH, Bakhtian KD, Fathi AR, Smith RK, Devroom HL, Nahavandi M, Woo S, Figg WD, Lonser RR. Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. Plos One. 6: e14504. PMID 21249218 DOI: 10.1371/Journal.Pone.0014504  0.315
2011 Kaneda K, Yamashita S, Woo S, Han TH. Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. Journal of Clinical Pharmacology. 51: 482-91. PMID 20498288 DOI: 10.1177/0091270010369242  0.32
2009 Woo S, Pawaskar D, Jusko WJ. Methods of utilizing baseline values for indirect response models. Journal of Pharmacokinetics and Pharmacodynamics. 36: 381-405. PMID 19697107 DOI: 10.1007/S10928-009-9128-6  0.652
2009 Dahut WL, Aragon-Ching JB, Woo S, Tohnya TM, Gulley JL, Arlen PM, Wright JJ, Ventiz J, Figg WD. Phase I study of oral lenalidomide in patients with refractory metastatic cancer. Journal of Clinical Pharmacology. 49: 650-60. PMID 19451403 DOI: 10.1177/0091270009335001  0.331
2009 Mager DE, Woo S, Jusko WJ. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metabolism and Pharmacokinetics. 24: 16-24. PMID 19252333 DOI: 10.2133/Dmpk.24.16  0.598
2008 Woo S, Krzyzanski W, Duliege AM, Stead RB, Jusko WJ. Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers. Journal of Clinical Pharmacology. 48: 43-52. PMID 18025524 DOI: 10.1177/0091270007309702  0.442
2008 Woo S, Krzyzanski W, Jusko WJ. Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chemotherapy and Pharmacology. 62: 123-33. PMID 17891399 DOI: 10.1007/S00280-007-0582-9  0.487
2007 Woo S, Krzyzanski W, Jusko WJ. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). Journal of Pharmacokinetics and Pharmacodynamics. 34: 849-68. PMID 17943422 DOI: 10.1007/S10928-007-9074-0  0.514
2007 Woo S, Jusko WJ. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 1672-8. PMID 17576810 DOI: 10.1124/Dmd.107.015248  0.494
2006 Woo S, Krzyzanski W, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. The Journal of Pharmacology and Experimental Therapeutics. 319: 1297-306. PMID 16973883 DOI: 10.1124/Jpet.106.111377  0.522
2006 Krzyzanski W, Woo S, Jusko WJ. Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans. Journal of Pharmacokinetics and Pharmacodynamics. 33: 125-66. PMID 16565883 DOI: 10.1007/S10928-006-9007-3  0.467
Show low-probability matches.